CRANBURY, N.J., May 12, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) will host a conference call and webcast on May 16, 2011 at 11:00 a.m. Eastern Time to discuss its quarter ended March 31, 2011 financial results and its programs, focusing on the upcoming start of its Phase 2 clinical trial with bremelanotide for women with female sexual dysfunction.
|
Schedule for the Financial Results Press Release, Conference Call / Webcast |
||
|
Q3 Fiscal Year 2011 Conference Call-Live |
5/16/2011 at 11:00 a.m. ET |
|
|
Domestic Dial-In Number |
1-866-316-1363 |
|
|
International Dial-In Number |
1-913-312-0861 |
|
|
Pass code |
2950108 |
|
|
Q3 Fiscal Year 2011 Conference Call-Replay |
5/16-5/23/2011 |
|
|
Domestic Dial-In Number |
1-888-203-1112 |
|
|
International Dial-In Number |
1-719-457-0820 |
|
|
Pass code |
2950108 |
|
|
Webcast Live and Replay Access |
http://www.palatin.com |
|
|
The webcast and replay can be accessed by logging on to the “Investor/Media Center-Webcasts” section of Palatin’s website at http://www.palatin.com |
||
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies’ website at www.palatin.com.
SOURCE Palatin Technologies, Inc.